Literature DB >> 2138923

Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study.

A J Thompson1, A G Kermode, D G MacManus, B E Kendall, D P Kingsley, I F Moseley, W I McDonald.   

Abstract

OBJECTIVE: To compare the abnormalities shown by magnetic resonance imaging of the brain in three clinically distinct groups of patients with multiple sclerosis, and to correlate the extent of abnormality with the degree of clinical disability in the three groups.
DESIGN: All patients underwent magnetic resonance imaging and full neurological examination, and their disability was scored according to the expanded Kurtzke disability state scale.
SETTING: National Hospital for Nervous Diseases (Multiple Sclerosis NMR Research Group). PATIENTS: Three groups of patients with confirmed multiple sclerosis were studied: 12 patients with minimal disability despite a long (greater than 10 years) duration of illness (benign multiple sclerosis), 16 who had developed progressive disability after a relapsing and remitting course (secondary progressive multiple sclerosis), and 13 who had had progressive disability from the onset of the disease (primary progressive multiple sclerosis). MAIN OUTCOME MEASURES: Number and size of lesions in 17 anatomically defined sites; total lesion load, estimated with an arbitrary scoring system weighted for the size of lesions; and disability score.
RESULTS: Magnetic resonance imaging showed that all 41 patients had abnormalities. These were extensive in the groups with secondary progressive and benign disease compared with the group with primary progressive disease. The lesions in the patients with secondary progressive disease were larger and more confluent than those in the two other groups (p = 0.007). Most lesions (85%) in the patients with primary progressive disease were under 5 mm in diameter; this percentage was higher than that in the two other groups (p = 0.032). Consequently the patients with primary progressive disease had the lowest mean lesion load (36.7); that in the patients with benign disease was 52.7 and that in the patients with secondary progressive disease 64.6 (p = 0.05). No correlation existed between disability and total lesion load. The distribution of brain lesions and of detectable lesions of the spinal cord, and the frequency of cortical atrophy, were similar in all groups.
CONCLUSIONS: No relation was found between the degree of clinical disability and the extent of abnormality shown by magnetic resonance imaging: patients with clinically benign disease often had extensive abnormalities and those with primary progressive disease had surprisingly few lesions. Though magnetic resonance imaging increases knowledge of the disease process in multiple sclerosis and is invaluable in diagnosis, it is not helpful in predicting disability in individual patients.

Entities:  

Mesh:

Year:  1990        PMID: 2138923      PMCID: PMC1662448          DOI: 10.1136/bmj.300.6725.631

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  12 in total

1.  Pathogenesis of progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D G MacManus; D P Kingsley; B E Kendall; I F Moseley; W I McDonald
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

2.  Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features.

Authors:  R A Koopmans; D K Li; E Grochowski; P J Cutler; D W Paty
Journal:  Ann Neurol       Date:  1989-01       Impact factor: 10.422

3.  A clinical and laboratory study of benign multiple sclerosis.

Authors:  A J Thompson; M Hutchinson; J Brazil; C Feighery; E A Martin
Journal:  Q J Med       Date:  1986-01

4.  Correlation between NMR scan and brain slice data in multiple sclerosis.

Authors:  W A Stewart; L D Hall; K Berry; D W Paty
Journal:  Lancet       Date:  1984-08-18       Impact factor: 79.321

5.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

6.  HLA class II genes in chronic progressive and in relapsing/remitting multiple sclerosis.

Authors:  O Olerup; S Fredrikson; T Olsson; S Kam-Hansen
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

7.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

8.  The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study.

Authors:  I E Ormerod; D H Miller; W I McDonald; E P du Boulay; P Rudge; B E Kendall; I F Moseley; G Johnson; P S Tofts; A M Halliday
Journal:  Brain       Date:  1987-12       Impact factor: 13.501

9.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Authors:  D H Miller; P Rudge; G Johnson; B E Kendall; D G Macmanus; I F Moseley; D Barnes; W I McDonald
Journal:  Brain       Date:  1988-08       Impact factor: 13.501

10.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

Authors:  C Confavreux; G Aimard; M Devic
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

View more
  42 in total

1.  Multiple sclerosis and the mind.

Authors:  M A Ron; A Feinstein
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-01       Impact factor: 10.154

Review 2.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 3.  Immune mediators of chronic pelvic pain syndrome.

Authors:  Stephen F Murphy; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Nat Rev Urol       Date:  2014-04-01       Impact factor: 14.432

4.  Survey of the distribution of lesion size in multiple sclerosis: implication for the measurement of total lesion load.

Authors:  L Wang; H M Lai; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

5.  Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study.

Authors:  K Lauer; W Firnhaber
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

6.  The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis.

Authors:  J M Greer; M P Pender
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

7.  MRI findings in benign multiple sclerosis are variable.

Authors:  Sean J Pittock; John H Noseworthy; Moses Rodriguez
Journal:  J Neurol       Date:  2006-08-29       Impact factor: 4.849

8.  Multiple sclerosis presenting as late functional deterioration after poliomyelitis.

Authors:  E Chroni; R S Howard; C P Panayiotopoulos; G T Spencer
Journal:  Postgrad Med J       Date:  1995-01       Impact factor: 2.401

9.  Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study.

Authors:  Y Zoukos; T N Thomaides; D Kidd; M L Cuzner; A Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

10.  Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study.

Authors:  M Filippi; G J Barker; M A Horsfield; P R Sacares; D G MacManus; A J Thompson; P S Tofts; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1994-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.